Kaya Holdings, INC 10-Q quarterly reports

Kaya Holdings reported a significantly increased net loss for the nine months ended September 30, 2025, driven by non-cash derivative expenses, while strategically exiting its cannabis operations to focus on psychedelic treatments and digital assets.

Kaya Holdings, Inc. reported a significantly wider net loss for Q2 2025, driven by increased derivative liabilities and early-stage psychedelic business development, despite exiting its cannabis retail operations.

Kaya Holdings, Inc. reports a net loss for Q1 2025 as it transitions from cannabis retail to psychedelic treatment facilities, with a focus on The Sacred Mushroom facility.

Kaya Holdings reports a net loss for Q3 2024, primarily due to changes in derivative liabilities, as it transitions from cannabis operations to focus on its new psilocybin treatment center.

Kaya Holdings, Inc. has filed an amended quarterly report for the period ending June 30, 2024, to reflect the completion of a required accounting review, reporting a net income primarily due to changes in derivative liabilities.

Kaya Holdings reports a net income of $432,210 for the quarter ending June 30, 2024, primarily due to derivative liabilities, while transitioning from cannabis to psilocybin operations.

Kaya Holdings has filed an amended 10-Q report to correct date errors and has identified material weaknesses in its internal controls over financial reporting.

Kaya Holdings reported a net loss for Q1 2024, driven by changes in derivative liabilities, while preparing to launch its flagship psilocybin treatment center.